13.35
前日終値:
$13.49
開ける:
$13.5
24時間の取引高:
392.89K
Relative Volume:
0.42
時価総額:
$558.46M
収益:
-
当期純損益:
$-168.05M
株価収益率:
-2.6023
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
-2.98%
1か月 パフォーマンス:
-5.65%
6か月 パフォーマンス:
-15.67%
1年 パフォーマンス:
-70.79%
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
13.35 | 558.46M | 0 | -168.05M | -146.15M | -5.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
2024-11-05 | 開始されました | Jefferies | Buy |
2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-09-23 | 開始されました | Guggenheim | Buy |
2024-06-25 | 開始されました | Oppenheimer | Outperform |
2024-02-21 | 開始されました | William Blair | Outperform |
2023-12-08 | 開始されました | Wells Fargo | Overweight |
2023-07-31 | 開始されました | Wedbush | Outperform |
2023-07-26 | 開始されました | BofA Securities | Buy |
2023-02-14 | 開始されました | Cowen | Outperform |
2022-10-18 | 開始されました | Truist | Buy |
2022-07-26 | 開始されました | BTIG Research | Buy |
2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
2020-05-04 | 開始されました | H.C. Wainwright | Buy |
2020-05-04 | 開始されました | Jefferies | Buy |
2020-05-04 | 開始されました | Piper Sandler | Overweight |
2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com
KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize
Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa
ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com
Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan
Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus
Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks
Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com
Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times
Keros Therapeutics to return $375 million to shareholders - Investing.com
Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq
Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan
Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
Keros Therapeutics Inc (KROS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
大文字化:
|
ボリューム (24 時間):